CD30 Antibodies - Biotech, Pharma and Life Science Channel
CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. This receptor is expressed by activated, but not by resting, T and B cells. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.
CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus is a useful marker in distinguishing between these germ cell tumors. CD30 and CD15 are also expressed on classical Hodgkin Lymphoma cells.
CD30 is a promising target for antibody-based immunotherapy of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma. To overcome the limitations from currently available murine anti-CD30 monoclonal antibodies (mAbs), a new fully human anti-CD30 antibody was generated. The mAb 5F11 showed specific binding to CD30 (cluster A). The ADCC assays indicated dose-dependent lysis of L540 cells when 5F11 was combined with human effector cells. Upon cross-linking in vitro, 5F11 inhibited the growth of CD30-expressing cell lines. In vivo, treatment with 5F11 induced a marked growth delay or even a complete regression of established xenografted HL in SCID mice. In the disseminated HL model, a high proportion of 5F11-treated mice experienced long-term survival. The new human anti-CD30 monoclonal antibody 5F11 shows promise as a means of CD30-targeted immunotherapy of malignant lymphomas. Based on these results, a clinical phase 1 study in patients with refractory CD30+ lymphoma has been initiated.
Source; Blood. 2003 Nov 15;102(10):3737-42. Borchmann et al
News Articles
− Analysis showed more than 60 percent of patients achieved longer progression-free survival following treatment with ADCETRIS compared to prior therapy − Takeda Ph...
VGTI Florida Scientists to Receive $3.6 Million in NIH Research Grants
Scientists at the Vaccine & Gene Therapy Institute of Florida (VGTI Florida®) have been awarded three new federal research grants that will further support the Institute’s...
Gram Scale Transient Antibody Production in CHO Cells with MaxCyte Electroporation
Dr. Hua Tu, CEO of LakePharma, and Dr. Peer Heine, Applications Scientist at MaxCyte, to Present Data Demonstrating Superior Performance and Scalability of MaxCyte Flow Electropor...
KaloBios Appoints Donald R. Joseph as Chief Legal Officer
SAN FRANCISCO, June 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Donald R. Joseph as Chief Legal Officer. Mr. Joseph brings to K...
PDL BioPharma Completes Regular Quarterly Dividend Payment
INCLINE VILLAGE, Nev., June 12, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 12, 2013, regular quarterly dividend payment of $0.15 per s...
Immunomedics Reports Progress With Labeling Proteins, Including Antibodies, for Improved PET Imaging
VANCOUVER, British Columbia, June 12, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products...
Algeta to evaluate novel Targeted Thorium Conjugate (TTC) based on Avipep's Avibody platform
Oslo, Norway, 11 June 2013 - Algeta ASA (OSE: ALGETA) announces a collaboration with Australian biotechnology company Avipep Pty Ltd to evaluate a novel Targeted Thorium Conjugate (TTC) based on com...
Trial Rationale Supported by Encouraging Data Reported on the Activity and Tolerability of ADCETRIS in the Treatment of Salvage HL Seattle Genetics, Inc. (Nasdaq:SGEN)...
Avaxia Biologics Closes Series B Financing with Total Proceeds of $11.4 Million
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company closed its Series B financing with...
Fabrus Scientists' Work Published in Journal Cell
LA JOLLA, Calif., June 6, 2013 /PRNewswire/ -- Fabrus Inc., a company developing a next-generation antibody discovery platform that expands the therapeutic applications of antibodies, today...
Events
6TH ANNUAL RECOMBINANT ANTIBODIES Conference
An insight into novel therapeutics and future technologies
Companies
ADC Therapeutics sarl (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major...
OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. Our appr...
Symphogen A/S, the biotech company pioneering recombinant human polyclonal antibodies for the treatment and prevention of human disease, today announced the initial closing of a USD 25 million Series...
Source BioScience LifeSciences
Source BioScience LifeSciences are European leaders in DNA sequencing, genomic services, bioinformatic analyses and offers a comprehensive portfolio of genomic reagents and antibodies. Source Bio...
Onconova, based in Newtown, PA and Lawrenceville, NJ, discovers and develops novel patent- protected small molecule therapeutic agents for cancer, radiation protection and hematol...
Itero Biopharmaceuticals, Inc.
Itero Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of protein therapeutics that offer significant clinical an...
CytomX Therapeutics is an early stage biotechnology company developing Probodiesâ¢, or proteolytically-activated antibodies. Probodies combine the well-established power and s...
Rockland Immunochemicals has supported the biopharma and diagnostic industries for over 40 years with antibodies and antibody based toolsâ¢Â for basic research, assay develo...
Hycult Biotech is a leader in the fields of immunology and cell biology, we develop, produce and market antibodies, antibody based products and more specifically immunoassays for...
Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Our products incorporate a proprietary âSialic Switchâ te...
Clinical Trials
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Complete responses with third-line or later salvage chemotherapy (CT) for germ cell tumors (GCT) range 0% to 10% and are usually short-lived and nearly all patients (pts) progressing after...
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) ma...
Intensified Post Remission Therapy Containing PEG-Asparaginase
This study is for patients with recently diagnosed blood cancer, called acute lymphoblastic leukemia (ALL). The standard treatment for this disease consists of many chemotherapy drugs tha...
The purpose of this study is to assess the seropersistence of TBE antibodies in children and adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34 months...
Rituximab in the Treatment of Graves' Disease
Aim: In a phase II pilot study encompassing 20 patients with Graves’ disease to evaluate the effect of rituximab: 1. Biochemically as assessed by markers of disease activity ( fr...
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With in-Vitro Bispecific Antibodies.
Patients with resistant metastatic solid tumors failing all conventional modalities who are eligible for immunotherapy by bispecific antibodies. First step: NST Second step: Patients with...
Human thyroglobulin (Tg) is the most sensitive biochemical marker for recurrence of differentiated cancer (DTC), especially after the complete removal of thyroid tissue through surgery and...
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Monoclonal ant...
Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease
This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease patient...
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B), can find tumor cells and carry tumor-killing substances to them withou...
PubMed Articles
This study determined the prevalence of classical onconeural Ab in a series of 2063 consecutive patients that were investigated because of suspicion of PNS as well as evaluated individual onconeural A...
Heavy neurofilaments (NFH) released from neurons during axonal injury induce a humoral immune response. We measured CSF and serum levels of NFH proteins and anti-NFH IgG antibodies in 19 patients with...
GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis.
Gamma-aminobutyric-acid B (GABA-B)-receptor encephalitis represents a novel entity among autoimmune CNS disorders. Most cases are characterised by limbic encephalitis.
The question of whether cannabinoid CB2 receptors are expressed on neurons in the brain and under what circumstances they are expressed is controversial in cannabinoid neuropharmacology. While some st...
The mechanism by which antibodies elicited against protein-derived peptides achieve cross-reactivity with their cognate proteins remains unknown. To address this question, we have carried out the comp...
Hepatitis C virus (HCV) infection is a major cause of liver disease and hepatocellular carcinoma. Glycan shielding has been proposed to be a mechanism by which HCV masks broadly neutralizing epitopes...
A new technique that uses gold immunochromatographic strips enhances the detection sensitivity by inducing the clustering of additional gold nanoparticles (AuNPs) around the immunogold particles immob...
In order to create an effective immunization approach for a potential vaccine to heroin, liposomes containing monophosphoryl lipid A [L(MPLA)] were tested as an adjuvant system to induce antibodies to...
Humoral immune response to oral rabies vaccination in raccoon kits: Problems and implications.
Little is known about the immunogenicity of RABORAL V-RG(®) (V-RG), an oral rabies vaccine, in raccoon kits (Procyon lotor). The objectives of this study were to characterize the immunogenicity of V-...
A chimeric protein was constructed expressing three epitopes of LiD1, a dermonecrotic toxin from the venom of Loxosceles intermedia spider. This species is responsible for a large number of accidents...
Videos
Dr. Advani Discusses CD30 as a Target and Brentuximab Vedotin in ALCL
Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses targeting CD30 as a target and the use of brentuximab vedotin in anapl...
Medical and Biotech [MESH] Definitions
Hepatitis A Antibodies
Antibodies to the HEPATITIS A ANTIGENS including antibodies to envelope, core, and non-structural proteins.
Lectins
Proteins that share the common characteristic of binding to carbohydrates. Some ANTIBODIES and carbohydrate-metabolizing proteins (ENZYMES) also bind to carbohydrates, however they are not considered lectins. PLANT LECTINS are carbohydrate-binding proteins that have been primarily identified by their hemagglutinating activity (HEMAGGLUTININS). However, a variety of lectins occur in animal species where they serve diverse array of functions through specific carbohydrate recognition.
Oligoclonal Bands
Multiple protein bands serving as markers of specific ANTIBODIES and detected by ELECTROPHORESIS of CEREBROSPINAL FLUID or serum. The bands are most often seen during inflammatory or immune processes and are found in most patients with MULTIPLE SCLEROSIS.
Antibodies, Phospho-specific
Antibodies directed against immunogen-coupled phosphorylated PEPTIDES corresponding to amino acids surrounding the PHOSPHORYLATION site. They are used to study proteins involved in SIGNAL TRANSDUCTION pathways. (From Methods Mol Biol 2000; 99:177-89)
Plantibodies
Recombinant antibodies produced in TRANSGENIC PLANTS. The plants serve as BIOREACTORS to produce the antibodies for medical use or industrial processes.
